The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Yatagarasu: A single-arm, open-label, phase 2 study of apalutamide (APA) plus goserelin (GOS) for patients (pts) with far locally advanced or recurrent/metastatic (fLA/RM) and androgen receptor (AR)-expressing salivary gland carcinoma (SGC).
 
Yoshitaka Honma
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Merck Serono; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Eisai; Janssen
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Merck Serono; MSD; Novartis; Ono Pharmaceutical
Research Funding - Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma; GlaxoSmithKline; Janssen; MSD; Novartis; Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical
 
Nobuya Monden
No Relationships to Disclose
 
Keisuke Yamazaki
No Relationships to Disclose
 
Satoshi Kano
No Relationships to Disclose
 
Hironaga Satake
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Shigenori Kadowaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Merck KGaA; Ono Pharmaceutical; Yakult Pharmaceutical
Research Funding - Chugai Pharma (Inst); Lilly (Inst); MSD (Inst); Nobelpharma (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Toshitaka Nagao
No Relationships to Disclose
 
Tomohiko Nakatogawa
Employment - Janssen
 
Koji Fujii
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
Patents, Royalties, Other Intellectual Property - A method of treating salivary gland carcinoma by using a combination of androgen deprivation therapy with a second generation anti-androgen receptor, apalutamide.
 
Yosuke Koroki
Employment - Janssen; Yakult Honsha
Stock and Other Ownership Interests - Johnson & Johnson
 
Junya Aoyama
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Patents, Royalties, Other Intellectual Property - A method of treating salivary gland carcinoma by using a combination of androgen deprivation therapy with a second generation anti-androgen receptor, apalutamide.
 
Shohei Ouchi
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Tetsuro Ogawa
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Sharon McCarthy
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Sabine D. Brookman-May
Employment - Janssen Research & Development
Leadership - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Suneel Mundle
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Jinhui Li
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Yuichiro Tada
No Relationships to Disclose